{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:41:42Z","timestamp":1792431702597,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,3,26]],"date-time":"2027-03-26T00:00:00Z","timestamp":1806019200000},"content-version":"am","delay-in-days":329,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["CTN-0102XR"],"award-info":[{"award-number":["CTN-0102XR"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015615","name":"National Institute on Drug Abuse Clinical Trials Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015615","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.cct.2026.108288","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T16:01:28Z","timestamp":1773676888000},"page":"108288","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Randomized controlled pilot trial of extended-release buprenorphine vs. sublingual buprenorphine-naloxone in rural settings (RXR): Study rationale and design"],"prefix":"10.1016","volume":"164","author":[{"given":"Larissa J.","family":"Mooney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Saxon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison J.","family":"Ober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitra","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robrina","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"McCormack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Scheele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yih-Ing","family":"Hser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cct.2026.108288_bb0005","series-title":"Drug Overdose Deaths","author":"Centers for Disease Control and Prevention, National Vital Statistics System","year":"2025"},{"issue":"Part 2","key":"10.1016\/j.cct.2026.108288_bb0020","article-title":"Long-acting buprenorphine injectables: opportunity to improve opioid use disorder treatment among rural populations","volume":"152","author":"Lowfall","year":"2021","journal-title":"Prev. Med."},{"issue":"1","key":"10.1016\/j.cct.2026.108288_bb0010","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/jrh.12328","article-title":"Overcoming barriers to prescribing buprenorphine for the treatment of opioid use disorder: recommendations from rural physicians","volume":"35","author":"Andrilla","year":"2019","journal-title":"J. Rural Health"},{"issue":"5","key":"10.1016\/j.cct.2026.108288_bib106","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/ADM.0000000000000045","article-title":"A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world","volume":"8","author":"Lowfall","year":"2014","journal-title":"J. Addict. Med."},{"key":"10.1016\/j.cct.2026.108288_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108131","article-title":"Geographic proximity to buprenorphine treatment providers in the U.S","volume":"213","author":"Langabeer","year":"2020","journal-title":"Drug Alcohol Depend."},{"issue":"8","key":"10.1016\/j.cct.2026.108288_bb0025","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1111\/add.14636","article-title":"Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorder","volume":"114","author":"Frost","year":"2019","journal-title":"Addiction"},{"issue":"10173","key":"10.1016\/j.cct.2026.108288_bib108","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0140-6736(18)32259-1","article-title":"Efficacy and safety of a monthly buprenoprhine depot injection for opioid use disorder: a multicentre, randomized, double blind, placebo-controlled, phase 3 trial","volume":"393","author":"Haight","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.cct.2026.108288_bb0030","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jamainternmed.2018.1052","article-title":"Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: a randomized clinical trial","volume":"178","author":"Lofwall","year":"2018","journal-title":"JAMA Intern. Med."},{"issue":"6","key":"10.1016\/j.cct.2026.108288_bib107","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jamainternmed.2018.1052","article-title":"Weekly and monthly subcutaneous buprenorphine with naloxone for treatment of opioid use disorder: a randomized clinical trial","volume":"178","author":"Lofwall","year":"2018","journal-title":"JAMA Intern. Med."},{"issue":"5","key":"10.1016\/j.cct.2026.108288_bb0035","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.9041","article-title":"Patient-reported outcomes of treatment of opioid dependence with weekly and monthly subcutaneous depot vs daily sublingual buprenorphine","volume":"4","author":"Lintzeris","year":"2021","journal-title":"JAMA Netw. Open"},{"issue":"2","key":"10.1016\/j.cct.2026.108288_bb0040","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10488-010-0319-7","article-title":"Outcomes for implementation research: conceptual distinctions, measurement challenges, and research agenda","volume":"38","author":"Proctor","year":"2011","journal-title":"Adm. Policy Ment. Health"},{"issue":"1","key":"10.1016\/j.cct.2026.108288_bb0045","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12913-017-2031-8","article-title":"Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework","volume":"17","author":"Sekhon","year":"2017","journal-title":"BMC Health Serv. Res."},{"issue":"9","key":"10.1016\/j.cct.2026.108288_bb0050","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1001\/archgenpsychiatry.2012.1a","article-title":"Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence","volume":"69","author":"Krupitsky","year":"2012","journal-title":"Arch. Gen. Psychiatry"},{"issue":"10118","key":"10.1016\/j.cct.2026.108288_bb0055","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.cct.2026.108288_bb0060","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1477-7525-2-12","article-title":"Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease","volume":"2","author":"Atkinson","year":"2004","journal-title":"Health Qual. Life Outcomes"},{"issue":"2","key":"10.1016\/j.cct.2026.108288_bb0105","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s11414-021-09776-y","article-title":"Development and measurement of the treatment perceptions survey (TPS) for clients with substance use disorders","volume":"49","author":"Teruya","year":"2022","journal-title":"J. Behav. Health Serv. Res."},{"key":"10.1016\/j.cct.2026.108288_bb0065","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13012-022-01245-0","article-title":"The updated Consolidated Framework for Implementation Research based on user feedback","volume":"17","author":"Damschroder","year":"2022","journal-title":"Implement. Sci."},{"issue":"2","key":"10.1016\/j.cct.2026.108288_bb0070","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1191\/1478088706qp063oa","article-title":"Using thematic analysis in psychology","volume":"3","author":"Braun","year":"2006","journal-title":"Qual. Res. Psychol."},{"issue":"1","key":"10.1016\/j.cct.2026.108288_bb0075","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cdp.2005.12.001","article-title":"Recruitment and participation in clinical trials: socio-demographic, rural\/urban, and health care access predictors","volume":"30","author":"Baquet","year":"2006","journal-title":"Cancer Detect. Prev."},{"issue":"1","key":"10.1016\/j.cct.2026.108288_bb0100","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1080\/10810730.2014.908985","article-title":"Barriers to medical research participation as perceived by clinical trial investigators: communicating with rural and African American communities","volume":"20","author":"Tanner","year":"2015","journal-title":"J. Health Commun."},{"issue":"2","key":"10.1016\/j.cct.2026.108288_bb0080","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3390\/healthcare10020223","article-title":"Machine learning for predicting risk of early dropout in a recovery program for opioid use disorder","volume":"10","author":"Gottlieb","year":"2022","journal-title":"Healthcare (Basel)"},{"issue":"3","key":"10.1016\/j.cct.2026.108288_bb0085","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0376-8716(03)00167-4","article-title":"Short-term alcohol and drug treatment outcomes predict long-term outcome","volume":"71","author":"Weisner","year":"2003","journal-title":"Drug Alcohol Depend."},{"issue":"4","key":"10.1016\/j.cct.2026.108288_bb0090","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/jat\/bkab033","article-title":"ELISA screens for fentanyl in urine are susceptible to false-positives in high concentration methamphetamine samples","volume":"46","author":"Abbott","year":"2022","journal-title":"J. Anal. Toxicol."},{"issue":"2","key":"10.1016\/j.cct.2026.108288_bb0095","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/ADM.0000000000000723","article-title":"Non-prescription fentanyl positive toxicology: prevalence, positive predictive value of fentanyl immunoassay screening, and description of co-substance use","volume":"15","author":"Kerensky","year":"2021","journal-title":"J. Addict. Med."}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714426000741?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714426000741?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T10:34:54Z","timestamp":1779446094000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714426000741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":24,"alternative-id":["S1551714426000741"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2026.108288","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized controlled pilot trial of extended-release buprenorphine vs. sublingual buprenorphine-naloxone in rural settings (RXR): Study rationale and design","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2026.108288","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108288"}}